Medtronic's Innovation Flywheel Lifts Top Line to a Decade High
Medtronic's fiscal Q4 delivered a clear message: the multi-year bet on a portfolio of high-growth medical technologies is now translating into sustained top-line acceleration. Revenue rose 9.9% reported and 6.6% organically to $9.8B, capping a fiscal year that saw the strongest growth in a decade. The market has long treated MDT as a slow-growth incumbent, but the numbers and the guided trajectory for FY27 are beginning to change that narrative.
The CAS Flywheel Accelerates
The most striking driver was Cardiac Ablation Solutions (CAS). Geoff Martha described the quarter as 'outstanding,' with “CAS delivered another outstanding quarter, with 78% worldwide growth and gaining an additional 8 points of U.S. share.” — Geoffrey Martha · 2026-06-03 Pulse field ablation (PFA) grew 145%, and the Affera installed base expanded 40% sequentially. The company is now annualizing over $2 billion in CAS revenue, and with the Sphere 360 single-shot catheter launching in Europe and the early innings of Affera's U.S. rollout, the runway remains long. Thierry Pieton noted the installed base expansion sets up a durable catheter pull-through.
Beyond CAS: Symplicity and Hugo
Outside CAS, the Symplicity renal denervation system reached an annualized revenue run rate of $100 million, with weekly procedure volumes doubling since the CMS National Coverage Determination. The physician finder now spans 200 doctors across 300 accounts, and “since the NCD, we have doubled average weekly procedure volumes.” — Geoffrey Martha · 2026-06-03 Hugo, the surgical robot, saw procedure volumes grow at 2-3x market, and submissions for general surgery and GYN indications were filed with the FDA. The Touch Surgery digital ecosystem surpassed 1,400 installations, up 30% sequentially. These are not just incremental wins; they represent the scaling of the Stealth AXiS platform and an expansion of the standard of care in multiple therapeutic areas.
Financial Execution and Guidance
The financial execution matched the operational momentum. Adjusted gross margin expanded to 65.4%, up 30 basis points year-over-year despite an 80 basis point tariff headwind. Operating margin of 25.5% reflected deliberate investment in R&D and M&A, and free cash flow reached $5.4 billion for the year—the strongest since 2022. The balance sheet holds $9.2 billion in cash and investments, providing ample dry powder for the tuck-in M&A strategy that has accelerated with deals like CathWorks, Scientia, and SPR Therapeutics.
For FY27, management guided to organic revenue growth of 6.75% to 7.25%, including the extra selling week, and EPS of $5.90 to $6.00. “Today, we're guiding fiscal year '27 organic revenue growth of 6.75% to 7.25%, including approximately 11.5% to 12% organic growth in the first quarter.” — Thierry Pieton · 2026-06-03 The guide embeds $250 million of tariff impact, a 2% M&A dilution, and does not yet capture the full benefit of the MiniMed separation.
We are not letting up. We are investing in the future. We are building momentum in our key growth areas, advancing innovations across the portfolio and deploying capital through targeted M&A, ventures and partnerships.
These results were not a bolt from the blue. In prior quarters, management consistently framed CAS, Symplicity, and Hugo as the pillars of a transformation. On the Q3 call, Thierry reaffirmed 'high single-digit EPS growth' for the coming year. “We're reiterating the high single-digit EPS growth guidance for '27.” — Geoffrey Martha, Chairman and CEO · 2026-02-17 The current quarter provides the first concrete proof of that acceleration at the top line. Back in August 2025, Geoff noted “We're still in the early innings of the launch of Affera in the U.S.” — Geoffrey Martha, Chairman and Chief Executive Officer · 2025-08-19 That early innings phase is now showing up in the numbers, and the guided trajectory suggests the innings are just beginning to matter for the overall revenue base.
The market has rewarded the shift—MDT shares are up about 7% over the last 90 days, with a steady upward trend, though still well below the 2021 peak. The task now is to sustain this momentum through FY27, where the extra week and MiniMed separation could distort the quarterly cadence. But if the execution holds, Medtronic's decade of innovation is finally translating into durable, top-line growth.